A western blot is a laboratory method used to detect ... The membrane is then incubated with an antibody called the primary antibody, which specifically binds to the protein of interest.

and B-cell maturation antigen (BCMA). Developed using Simcere’s T-cell engager polyspecific antibody technology platform, the therapy has demonstrated strong T-cell cytotoxicity against MM cells.

BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 ...

with then-CEO Richard Gonzalez telling analysts back in 2023 that the BCMA bispecific antibody T-cell engager ABBV-383 was driving the company’s “high level of interest” in the space.

SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized trispecific antibody that targets ...

BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 ...